24 research outputs found
Mesenchymal stem cells: from experiment to clinic
There is currently much interest in adult mesenchymal stem cells (MSCs) and their ability to differentiate into other cell types, and to partake in the anatomy and physiology of remote organs. It is now clear these cells may be purified from several organs in the body besides bone marrow. MSCs take part in wound healing by contributing to myofibroblast and possibly fibroblast populations, and may be involved in epithelial tissue regeneration in certain organs, although this remains more controversial. In this review, we examine the ability of MSCs to modulate liver, kidney, heart and intestinal repair, and we update their opposing qualities of being less immunogenic and therefore tolerated in a transplant situation, yet being able to contribute to xenograft models of human tumour formation in other contexts. However, such observations have not been replicated in the clinic. Recent studies showing the clinical safety of MSC in several pathologies are discussed. The possible opposing powers of MSC need careful understanding and control if their clinical potential is to be realised with long-term safety for patients
Antioxidant and Anti-Inflammatory Action of Stem Cells in Cardiac Disease
Cardiac diseases are the consequence of blockage of blood vessels, scar formation and ultimate loss of terminally differentiated cardiomyocytes. Immune cells and oxidative stress easily slow down the cardiac functions by manipulating the cardiac tissue matrix. Stem cell-based therapies, especially mesenchymal stem cells (MSCs), multipotential nonhematopoietic progenitor cells compensate the cardiac diseases by differentiating into multiple lineages of mesenchyme including cardiomyocytes and vascular endothelial cells. Antioxidant and anti-inflammatory action of MSCs has been explored recently by various research groups. Secretion of biomolecules by MSCs perturbs and prevents the initiation, development and the function of the inflammatory cascade. These molecules mainly act through Paracrine mode. Anti-inflammatory action of MSCs mediates the cardiac diseases and the current progress in elucidating the mechanism and clinical use will be focused in detail in this article
Hepatocyte growth factor incorporated chitosan nanoparticles differentiate murine bone marrow mesenchymal stem cell into hepatocytes in vitro
Delivery of growth factor for the differentiation of stem cells into lineage specific cells holds great potential in regenerative medicine. Stem cell differentiation is governed by cytokines and growth factors secreted upon the organelle injury and, however, their short half-life necessitates exogenous supply. Development of suitable nanodevices using biodegradable polymers to deliver therapeutic proteins to the targeted site in a sustainable manner attracts scientists and clinicians. Here, for the first time, hepatocyte growth factor (HGF) was incorporated into chitosan nanoparticles (CNP) by ionotrophic gelation method. An average size of nanoparticles prepared was 100 nm, showing sustainable release of HGF. Cytotoxicity study did not reveal any adverse effect on bone marrow mesenchymal stem cells (MSC) up to 4 mg CNP/ml culture medium. To evaluate the effect of HGF incorporated CNP (HGF-CNP) on hepatic differentiation in in vitro, MSC were incubated with HGF-CNP and other supplements. After 21 days, fibroblast-like morphology of MSC became round-shape, a typical characteristic of hepatocyte cell. Immunofluorescence study for albumin expression confirmed the hepatic differentiation. In conclusion, HGF released from the HGF-CNP can differentiate MSC into hepatocytes, and this novel technique could also be extended to deliver therapeutic proteins for a variety of tissue regeneration
Chitosan nanoparticles as a dual growth factor delivery system for tissue engineering applications
Sustainable delivery of therapeutic as well as functional proteins is largely required in the pharmacological and regenerative medicine. Here we have prepared chitosan nanoparticles (CNP) and incorporated growth factors such as epidermal growth factor (EGF) and fibroblast growth factor (FGF), either individually or in combination, which could ultimately be impregnated into engineered tissue construct. CNP was characterized by Fourier transform infrared (FTIR) spectroscopy, Zeta sizer and high resolution transmission electron microscope (HRTEM). The particles were in the size range of 50-100 nm with round and flat shape. The release kinetics of both EGF and FGF incorporated CNP showed the release of growth factors in a sustained manner. Growth factors incorporated nanoparticles did not show any toxicity against fibroblasts up to 4 mg/ml culture medium. Increased proliferation of fibroblasts in vitro evidenced the delivery of growth factors from CNP for cellular signaling. Western blotting results also revealed the poor inflammatory response showing less expression of proinflammatory cytokines such as IL-6 and TNFα in the macrophage cell line J774 A-1
Production of Neutrophil Extracellular Traps Contributes to the Pathogenesis of Francisella tularemia
10.3389/fimmu.2020.00679Frontiers in Immunology1167
Neutrophils induce a novel chemokine receptors repertoire during influenza pneumonia
10.3389/fcimb.2019.00108Frontiers in Cellular and Infection Microbiology9MAR10
Mesenchymal Stem Cells and Osteoarthritis: Remedy or Accomplice?
Multipotent mesenchymal stromal or stem cells (MSCs) are likely to be agents of connective tissue homeostasis and repair. Because the hallmark of osteoarthritis (OA) is degeneration and failure to repair connective tissues it is compelling to think that these cells have a role to play in OA. Indeed, MSCs have been implicated in the pathogenesis of OA and, in turn, progression of the disease has been shown to be therapeutically modulated by MSCs. This review discusses current knowledge on the potential of both marrow- and local joint-derived MSCs in OA, the mode of action of the cells, and possible effects of the osteoarthritic niche on the function of MSCs. The use of stem cells for repair of isolated cartilage lesions and strategies for modulation of OA using local cell delivery are discussed as well as therapeutic options for the future to recruit and appropriately activate endogenous progenitors and/or locally systemically administered MSCs in the early stages of the disease. The use of gene therapy protocols, particularly as they pertain to modulation of inflammation associated with the osteoarthritic niche, offer an additional option in the treatment of this chronic disease. In summary, elucidation of the etiology of OA and development of technologies to detect early disease, allied to an increased understanding of the role MSCs in aging and OA, should lead to more targeted and efficacious treatments for this debilitating chronic disease in the future.This work was funded by Science Foundation Ireland, Centre for Science Engineering and Technology award (CSET) in Regenerative MedicineDeposited by bulk impor
Therapeutic effect of hepatocyte growth factor-overexpressing bone marrow-derived mesenchymal stem cells on CCl4-induced hepatocirrhosis.
Distribution pattern following systemic mesenchymal stem cell injection depends on the age of the recipient and neuronal health
This is an Open Access Article. It is published by BioMed Central under the Creative Commons Attribution 4.0 International Licence (CC BY). Full details of this licence are available at: http://creativecommons.org/licenses/by/4.0/BACKGROUND: Mesenchymal stem cells (MSCs) show therapeutic efficacy in many different age-related degenerative diseases, including Alzheimer's disease. Very little is currently known about whether or not aging impacts the transplantation efficiency of MSCs. METHODS: In this study, we investigated the distribution of intravenously transplanted syngeneic MSCs derived from young and aged mice into young, aged, and transgenic APP/PS1 Alzheimer's disease mice. MSCs from male donors were transplanted into female mice and their distribution pattern was monitored by PCR using Y-chromosome specific probes. Biodistribution of transplanted MSCs in the brains of APP/PS1 mice was additionally confirmed by immunofluorescence and confocal microscopy. RESULTS: Four weeks after transplantation into young mice, young MSCs were found in the lung, axillary lymph nodes, blood, kidney, bone marrow, spleen, liver, heart, and brain cortex. In contrast, young MSCs that were transplanted into aged mice were only found in the brain cortex. In both young and aged mouse recipients, transplantation of aged MSCs showed biodistribution only in the blood and spleen. Although young transplanted MSCs only showed neuronal distribution in the brain cortex in young mice, they exhibited a wide neuronal distribution pattern in the brains of APP/PS1 mice and were found in the cortex, cerebellum, hippocampus, olfactory bulb, and brainstem. The immunofluorescent signal of both transplanted MSCs and resident microglia was robust in the brains of APP/PS1 mice. Monocyte chemoattractant-1 levels were lowest in the brain cortex of young mice and were significantly increased in APP/PS1 mice. Within the hippocampus, monocyte chemoattractant-1 levels were significantly higher in aged mice compared with younger and APP/PS1 mice. CONCLUSIONS: We demonstrate in vivo that MSC biodistribution post transplantation is detrimentally affected by aging and neuronal health. Aging of both the recipient and the donor MSCs used attenuates transplantation efficiency. Clinically, our data would suggest that aged MSCs should not be used for transplantation and that transplantation of MSCs into aged patients will be less efficacious